Wells Trecaso Financial Group LLC Has $4.81 Million Holdings in McKesson Corporation $MCK

Wells Trecaso Financial Group LLC decreased its stake in shares of McKesson Corporation (NYSE:MCK) by 42.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 6,225 shares of the company’s stock after selling 4,503 shares during the period. McKesson accounts for about 2.3% of Wells Trecaso Financial Group LLC’s holdings, making the stock its 15th largest position. Wells Trecaso Financial Group LLC’s holdings in McKesson were worth $4,809,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MCK. Vanguard Group Inc. boosted its holdings in shares of McKesson by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after buying an additional 232,286 shares during the period. Geode Capital Management LLC boosted its holdings in McKesson by 4.1% during the second quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock valued at $2,057,065,000 after acquiring an additional 112,224 shares during the period. Alliancebernstein L.P. increased its stake in shares of McKesson by 150.4% in the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after purchasing an additional 1,362,386 shares during the period. Norges Bank acquired a new position in shares of McKesson during the 2nd quarter worth about $1,346,661,000. Finally, Arrowstreet Capital Limited Partnership boosted its stake in McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after purchasing an additional 446,060 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results beat and company raised FY26 adjusted EPS guidance to $38.80–$39.20, driven by oncology/specialty drug growth — confirms stronger-than-expected revenue/profit trajectory. Business Wire: Q3 Results & Guidance
• Positive Sentiment: Market reaction: shares jumped (~16% intraday) to record highs on the beat-and-raise, signaling strong investor confidence in specialty/tech initiatives. Investing: All‑time high
• Positive Sentiment: Reuters and other outlets highlight McKesson boosting its 2026 profit forecast citing specialty drug distribution and oncology services — supports sustainability of margin improvements. Reuters: Profit Forecast Boost
• Neutral Sentiment: Earnings transcripts, slide deck and call coverage provide color on specialty, tech investments and supply‑chain dynamics — useful for modeling but not immediate catalysts. MSN: Q3 Call Transcript
• Negative Sentiment: Some analysts raised price targets but kept neutral/equal‑weight ratings — Wells Fargo lifted its PT to $925 while keeping an “equal weight” call (PT still below current price), which may cap upside for some investors. American Banking News: Wells Fargo PT
• Negative Sentiment: Third‑party note flagged weak operating cash flow versus prior year and disclosed insider selling activity — potential governance/liquidity items investors will watch. Quiver Quant: Cash Flow & Insider Sales

Insider Activity at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

MCK has been the topic of several recent analyst reports. UBS Group lifted their price target on McKesson from $920.00 to $980.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Mizuho upped their target price on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research note on Thursday. Wells Fargo & Company increased their price target on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a report on Thursday. Barclays initiated coverage on shares of McKesson in a report on Monday, December 8th. They set an “overweight” rating and a $960.00 price objective on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $966.00 target price on shares of McKesson in a research note on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $918.93.

McKesson Stock Up 0.1%

NYSE:MCK opened at $958.76 on Friday. The firm has a market capitalization of $118.34 billion, a PE ratio of 27.57, a price-to-earnings-growth ratio of 1.35 and a beta of 0.40. McKesson Corporation has a 12-month low of $583.55 and a 12-month high of $971.93. The firm has a 50-day moving average price of $827.03 and a 200 day moving average price of $777.93.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 303.62% and a net margin of 1.09%.The company had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period in the prior year, the company posted $8.03 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts expect that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.